Eye infection drug IND accepted

Article

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from Alcon to NovaBay of $1 million.

The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from the firm's license partner Alcon to NovaBay of $1 million.

NVC-422 - a molecule in the non-antibiotic anti-infective Aganocide class - has been shown in vitro to combat bacteria (including multi-drug-resistant strains), viruses, yeasts and fungi, and has been proven safe for ocular use in previous in vivo testing. NovaBay hopes that NVC-422 will have applications against both bacterial and viral conjunctivitis, to be used topically in the eye as well as within contact lens solution.

NVC-422 is currently also under investigation for non-ocular indications, including skin infections caused by the "superbug" MRSA.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.